SCHEMBL2164231

SCHEMBL2164231

Fc1ccc(Nc2nnnc3ccccc23)cc1Cl

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 6/20 0.67
ABCG2 Q9UNQ0 1/20 0.63
MEN1 O00255 1/20 0.57
RAB9A P51151 1/20 0.57
KMT2A Q03164 1/20 0.57
CTDSP1 Q9GZU7 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
SOS1 Q07889 7/20 0.52
ACP1 P24666 1/20 0.48
RXFP1 Q9HBX9 1/20 0.47
NPY5R Q15761 1/20 0.47
GRM1 Q13255 1/20 0.46
AURKA O14965 1/20 0.45
ERBB2 P04626 1/20 0.45
INSR P06213 1/20 0.45
FBP1 P09467 1/20 0.45
PDGFRB P09619 1/20 0.45
FLT4 P35916 1/20 0.45
KDR P35968 1/20 0.45
CLK1 P49759 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12401609 0.83 MEN1 (0.57) EGFRABCG2MEN1RAB9AKMT2A
SCHEMBL2164209 0.81 EGFR (0.65) EGFRABCG2MEN1RAB9AKMT2A
SCHEMBL2163667 0.81 MEN1 (0.65) EGFRABCG2MEN1RAB9AKMT2A
SCHEMBL2163049 0.81 MEN1 (0.56) EGFRABCG2MEN1RAB9AKMT2A
SCHEMBL1734685 0.81 EGFR (1.00) EGFRABCG2GRM1AURKAERBB2
SCHEMBL30301821 0.81 EGFR (1.00) EGFRABCG2GRM1AURKAERBB2
SCHEMBL2164699 0.81 MEN1 (0.57) EGFRABCG2MEN1RAB9AKMT2A
SCHEMBL2164245 0.79 MEN1 (0.70) EGFRABCG2MEN1RAB9AKMT2A
SCHEMBL2163688 0.78 MEN1 (0.60) EGFRABCG2MEN1RAB9AKMT2A
SCHEMBL2163650 0.76 EGFR (0.46) EGFRABCG2GRM1AURKAERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US claimed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP claimed
US-8349835-B2 Aromatic ring fused triazine derivatives and uses thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2013-01-08 US disclosed
US-8349835-B2 Aromatic ring fused triazine derivatives and uses thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2013-01-08 US disclosed
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US disclosed
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US disclosed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF KDR, FLT1, FLT4 EGFR 8/4885ABCG2 79/4885MEN1 2848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.